Clinical trials: Subjects With Hyperuricemia
Primary Gout and Hyperuricemia
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
SHR4640 tablets is a highly selective and potent URAT1 inhibitors. The study is being conducted to evaluate the efficacy, and safety of SHR4640 tablet combined with 40 mg/d febuxostat tablet in reducing uric acid in subjects with…
- Trial name
- NCT07362355
- Testing
- SHR4640 ；Febuxostat, SHR4640 ; Febuxostat, SHR4640
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gout
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult…
- Trial name
- NCT05690204
- Testing
- SAP-001
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Shanton Pharma Pte. Ltd.
Gout, Hyperuricemia
SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects
To evaluate the pharmacokinetics (PK) profile of single or multiple oral doses of SAP-001 tablets in healthy Chinese subjects and gout patients with hyperuricemia.
- Trial name
- NCT06678581
- Testing
- SAP-001
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Shanton Pharma Co., Ltd.
Gout, Hyperuricemia
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
This is a randomized, double-blind, 3-period crossover phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics (PK) and pharmacodynamics (PD) and to evaluate the…
- Trial name
- NCT00995618
- Testing
- Tranilast, Febuxostat, Combination - Tranilast and Febuxostat
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Nuon Therapeutics, Inc.
Hyperuricemia
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
The objective of the study is to assess efficacy and safety of SHR4640 in subjects with hyperuricemia.
- Trial name
- NCT03185793
- Testing
- SHR4640, benzbromarone
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gout, Hyperuricemia
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency.
- Conditions
- Gout, Hyperuricemia, Arthritis, Joint Disease
- Trial name
- NCT01407874
- Testing
- Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- BioCryst Pharmaceuticals
Asymptomatic Hyperuricemia
A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
The main purpose To evaluate the safety and tolerability of pegloticase in subjects with asymptomatic hyperuricemia by single intravenous infusion at different doses, and to provide a basis for multiple doses of Pegloticase in…
- Trial name
- NCT05302388
- Testing
- SIBP-R002, Dexamethasone or Methyl prednisolone, Diphenhydramine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Institute Of Biological Products
Hyperuricemia
Zurig (Febuxostat) 40mg Efficacy and Safety Trial
Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid.
- Trial name
- ZEST (NCT02600780)
- Testing
- Febuxostat, Allopurinol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Getz Pharma
Gout
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
- Trial name
- EXCEL (NCT00175019)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 1,086 people
- Sponsor
- Takeda
Gout
A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing
A phase 1 clinical trial of HEC93077,to evaluate the safety ,PK,PD and food effect in Chinese healthy subjects and HUA patients after single or multiple dosing.
- Trial name
- NCT05127772
- Testing
- HEC93077
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Gout
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
- Trial name
- NCT01129648
- Testing
- Allopurinol, BCX4208
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- BioCryst Pharmaceuticals
Joint Damage
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.
- Trial name
- NCT01078389
- Testing
- Febuxostat
- Where
- 56 sites in United States
- Volunteers
- 314 people
- Sponsor
- Takeda
Gout
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout.
- Trial name
- NCT00080210
- Testing
- Puricase
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Savient Pharmaceuticals
Gout Disease
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including…
- Trial name
- NCT07889284
- Testing
- Combined metabolic activators, Collagen and maltodextrin
- Where
- 12 sites in Turkey (Türkiye)
- Volunteers
- 336 people
- Sponsor
- ScandiBio Therapeutics AB
Gout Flares
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis.
- Trial name
- NCT01712204
- Testing
- AC-201, Febuxostat
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- TWi Biotechnology, Inc.
Hyperuricemia, Hypouricemia, Renal
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.
- Trial name
- NCT06310967
- Testing
- IG3018
- Where
- 6 sites in Australia, Taiwan
- Volunteers
- 60 people
- Sponsor
- Intelligem Therapeutics Australia Pty Ltd.
Hyperuricemia
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
The purpose of this study is to determine whether RDEA806 is effective in the treatment of hyperuricemia in gout patients.
- Trial name
- NCT00741442
- Testing
- RDEA806
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Ardea Biosciences, Inc.
Hypertension
Effect of Febuxostat on Blood Pressure
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with…
- Trial name
- NCT01496469
- Testing
- Febuxostat
- Where
- 45 sites in United States
- Volunteers
- 121 people
- Sponsor
- Takeda
Gout Chronic, Hyperuricemia
Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
This is an open label multicenter study to evaluate the safety and tolerability of multiple doses (3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase (SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple…
- Trial name
- NCT02959918
- Testing
- SEL-212, SEL-037, SVP-rapamycin (SEL-110)
- Where
- 13 sites in United States
- Volunteers
- 152 people
- Sponsor
- Selecta Biosciences, Inc.
Primary Gout and Hyperuricemia
Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
SHR4640 tablets is a highly selective and potent URAT1 inhibitors,study number is SHR4640-203. The primary purpose of the study is to evaluate the efficacy and safety of the combination of SHR4640 and febuxostat compared with…
- Trial name
- NCT05513976
- Testing
- SHR4640 tablet, febuxostat tablet
- Volunteers
- 129 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.